Oncomethylome Sciences achieves key milestone in Schering-Plough collaboration
Starting immediately, the laboratory will be evaluating the methylation status of the MGMT gene in DNA extracted from brain tumor cells using OncoMethylome Sciences' patent-protected assay. Making this testing service available is a key milestone in OncoMethylome Sciences' collaboration with Schering-Plough. The tumor samples will originate from the multi-center brain cancer clinical trial conducted by the U.S.-based Radiation Therapy Oncology Group (RTOG), the European Organization for Research and Treatment of Cancer (EORTC), and supported by Schering-Plough.
Most read news
Other news from the department business & finance
These products might interest you
Systec H-Series by Systec
Safe, reproducible and validatable sterilization of liquids, solids and waste
Autoclaves with 65-1580 liters usable space, flexibly expandable for various applications
Whatman™ folded filter papers by Cytiva
Whatman folded filter papers
Convenient folded formats speed up your sample preparation
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.